WASHINGTON / LONDON (IT BOLTWISE) – The US subsidiary of the German pharmaceutical company Merck has agreed with the US government to significantly reduce the costs of in vitro fertilization. This action follows an executive order from President Trump intended to increase access to IVF treatments. The agreement calls for EMD Serono, Merck’s US subsidiary, to sell its drugs directly to consumers at reduced prices.
Today’s daily deals at Amazon! ˗ˋˏ$ˎˊ˗
The US subsidiary of the German pharmaceutical company Merck, EMD Serono, has agreed with the US government on a significant reduction in the prices of drugs for in vitro fertilization (IVF). This decision is part of a broader Trump administration initiative aimed at increasing access to IVF treatments and reducing associated costs. The agreement provides for EMD Serono to sell its Gonal-f, Ovidrel and Cetrotide products directly to consumers at significantly reduced prices.
President Donald Trump signed an executive order in February directing the government to expand access to IVF and reduce the cost of the treatment. This measure is intended to help couples who want to have children cope with the high costs of up to $25,000 per cycle. In return for the discounts, Merck will invest in research and production in the US, which is also seen as a strategic move to strengthen the company’s presence in the US market.
The agreement between Merck and the US government is an example of the increasing importance of public-private partnerships in the healthcare sector. As the government tries to reduce healthcare costs, companies like Merck are benefiting from the opportunity to strengthen their market position while benefiting from possible tariff exemptions. This development could also encourage other companies to enter into similar agreements to reap the benefits of working with the government.
Merck’s decision to cut prices for IVF drugs could have far-reaching implications for the fertility treatment market. Experts expect that this could intensify competition in this area and possibly lead to further price reductions. In addition, the measure could also increase pressure on other pharmaceutical companies to lower their prices in order to remain competitive. In a market characterized by high costs and limited access, this development could represent an important step towards wider availability of fertility treatments.
*Order an Amazon credit card with no annual fee with a credit limit of 2,000 euros! a‿z
Bestseller No. 1 ᵃ⤻ᶻ “KI Gadgets”
Bestseller No. 2 ᵃ⤻ᶻ “KI Gadgets”
Bestseller No. 3 ᵃ⤻ᶻ “KI Gadgets”
Bestseller No. 4 ᵃ⤻ᶻ “KI Gadgets”
Bestseller No. 5 ᵃ⤻ᶻ “KI Gadgets”
Please send any additions and information to the editorial team by email to de-info[at]it-boltwise.de. Since we cannot rule out AI hallucinations, which rarely occur with AI-generated news and content, we ask you to contact us via email and inform us in the event of false statements or misinformation. Please don’t forget to include the article headline in the email: “Merck subsidiary lowers prices for IVF treatments in the USA”.
The post Merck subsidiary lowers prices for IVF treatments in the USA appeared first on Veritas News.
